Assignee
ARCUTIS BIOTHERAPEUTICS INC
US·23 granted patents·31 pending applications·67 citations·filing 2019–2025
Top patents by PatentIndex Score
54 records- 0199US11819496B2Topical roflumilast formulation having improved delivery and plasma half-lifeARCUTIS BIOTHERAPEUTICS INC·Filed 2023·Granted Nov 21, 2023·17 cites·20 claims
- 0298US12005052B2Topical roflumilast formulation having improved delivery and plasma half-lifeARCUTIS BIOTHERAPEUTICS INC·Filed 2023·Granted Jun 11, 2024·3 cites·9 claims
- 0398US12005051B2Topical roflumilast formulation having improved delivery and plasma half lifeARCUTIS BIOTHERAPEUTICS INC·Filed 2021·Granted Jun 11, 2024·4 cites·20 claims
- 0497US12042487B2Method for reducing side effects from administration of phosphodiesterase-4 inhibitorsARCUTIS BIOTHERAPEUTICS INC·Filed 2023·Granted Jul 23, 2024·4 cites·30 claims
- 0597US11992480B2Method for reducing side effects from administration of phosphodiesterase-4 inhibitorsARCUTIS BIOTHERAPEUTICS INC·Filed 2021·Granted May 28, 2024·8 cites·43 claims
- 0696US12310956B2Topical roflumilast formulation having improved delivery and plasma half-lifeARCUTIS BIOTHERAPEUTICS INC·Filed 2024·Granted May 27, 2025·1 cites·22 claims
- 0796US11730740B2Laureth-4 containing topical formulationsARCUTIS BIOTHERAPEUTICS INC·Filed 2021·Granted Aug 22, 2023·2 cites·16 claims
- 0892US12336983B2Inhibition of crystal growth of roflumilastARCUTIS BIOTHERAPEUTICS INC·Filed 2024·Granted Jun 24, 2025·0 cites·29 claims
- 0992US11707454B2Topical roflumilast formulation having antifungal propertiesARCUTIS BIOTHERAPEUTICS INC·Filed 2021·Granted Jul 25, 2023·16 cites·17 claims
- 1091US11628177B2Compositions and methods for deep dermal drug deliveryARCUTIS BIOTHERAPEUTICS INC·Filed 2021·Granted Apr 18, 2023·2 cites·16 claims
- 1190US12016848B2Roflumilast formulations with an improved pharmacokinetic profileARCUTIS BIOTHERAPEUTICS INC·Filed 2023·Granted Jun 25, 2024·3 cites·12 claims
- 1290US12011437B1Roflumilast formulations with an improved pharmacokinetic profileARCUTIS BIOTHERAPEUTICS INC·Filed 2024·Granted Jun 18, 2024·3 cites·19 claims
- 1389US12257242B2Inhibition of crystal growth of roflumilastARCUTIS BIOTHERAPEUTICS INC·Filed 2023·Granted Mar 25, 2025·0 cites·25 claims
- 1488US12220409B2Roflumilast formulations with an improved pharmacokinetic profileARCUTIS BIOTHERAPEUTICS INC·Filed 2024·Granted Feb 11, 2025·1 cites·30 claims
- 1587US12390453B2Method for reducing side effects from administration of phosphodiesterase-4 inhibitorsARCUTIS BIOTHERAPEUTICS INC·Filed 2024·Granted Aug 19, 2025·0 cites·23 claims
- 1687US12042558B2Method and formulation for improving roflumilast skin penetration lag timeARCUTIS BIOTHERAPEUTICS INC·Filed 2019·Granted Jul 23, 2024·3 cites·6 claims
- 1787US2025235435A1Inhibition of crystal growth of roflumilastARCUTIS BIOTHERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1885US12083122B2Laureth-4 containing topical formulationsARCUTIS BIOTHERAPEUTICS INC·Filed 2023·Granted Sep 10, 2024·0 cites·14 claims
- 1984US2025281471A1Topical roflumilast formulation having improved delivery and plasma half- lifeARCUTIS BIOTHERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2083US2024382504A1Treatment of skin conditions using high krafft temperature anionic surfactantsARCUTIS BIOTHERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2183US2025049771A1Method for reducing side effects from administration of phosphodiesterase-4 inhibitorsARCUTIS BIOTHERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2282US2024261308A1Treatment of skin conditions using high krafft temperature anionic surfactantsARCUTIS BIOTHERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2382US2025288569A1Method for reducing side effects from administration of phosphodiesterase-4 inhibitorsARCUTIS BIOTHERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2482US2024390380A1Laureth-4 containing topical formulationsARCUTIS BIOTHERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2582US2026014099A1Self-preserving topical pharmaceutical compositions comprising diethylene glycol monoethyl etherARCUTIS BIOTHERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2681US2023346690A1Method and Formulation for Improving Roflumilast Skin Penetration Lag TimeARCUTIS BIOTHERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2781US2023346689A1Method and Formulation for Improving Roflumilast Skin Penetration Lag TimeARCUTIS BIOTHERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2881US2023338275A1Method and Formulation for Improving Roflumilast Skin Penetration Lag TimeARCUTIS BIOTHERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2979US12053481B2Compositions and methods for deep dermal drug deliveryARCUTIS BIOTHERAPEUTICS INC·Filed 2023·Granted Aug 6, 2024·0 cites·19 claims
- 3079US2025312457A1Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solventsARCUTIS BIOTHERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3178US2024382502A1Compositions and methods for deep dermal drug deliveryARCUTIS BIOTHERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3278US2026027092A1Topical Roflumilast Aerosol FoamsARCUTIS BIOTHERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3377US12329751B2Topical roflumilast formulation having antifungal propertiesARCUTIS BIOTHERAPEUTICS INC·Filed 2023·Granted Jun 17, 2025·0 cites·40 claims
- 3477US2023310346A1Self-preserving topical pharmaceutical compositions comprising diethylene glycol monoethyl etherARCUTIS BIOTHERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3576US12453721B2Topical roflumilast aerosol foamsARCUTIS BIOTHERAPEUTICS INC·Filed 2022·Granted Oct 28, 2025·0 cites·19 claims
- 3676US2025127767A1Roflumilast Formulations with an Improved Pharmacokinetic ProfileARCUTIS BIOTHERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3775US2023091358A1Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solventsARCUTIS BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3875US2023285319A1Self-preserving topical pharmaceutical compositions comprising diethylene glycol monoethyl etherARCUTIS BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3974US2022211730A1Treatment of skin conditions using high krafft temperature anionic surfactantsARCUTIS BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4074US2026053821A1Pharmaceutical compositions of spironolactone for deep dermal drug deliveryARCUTIS BIOTHERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4174US2023310345A1Self-preserving topical pharmaceutical compositions comprising diethylene glycol monoethyl etherARCUTIS BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4273US12458652B2Pharmaceutical compositions of spironolactone for deep dermal drug deliveryARCUTIS BIOTHERAPEUTICS INC·Filed 2022·Granted Nov 4, 2025·0 cites·13 claims
- 4372US2025090509A1Methods of reducing itch using topical roflumilast compositionsARCUTIS BIOTHERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 4472US2025090508A1Methods of reducing itch using topical roflumilast compositionsARCUTIS BIOTHERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 4571US12161643B2Stable formulations of SHR0302ARCUTIS BIOTHERAPEUTICS INC·Filed 2022·Granted Dec 10, 2024·0 cites·14 claims
- 4671US12144802B2Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drugARCUTIS BIOTHERAPEUTICS INC·Filed 2023·Granted Nov 19, 2024·0 cites·20 claims
- 4771US2025352526A1Topical roflumilast formulation having antifungal propertiesARCUTIS BIOTHERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4871US2023134782A1Treatment of skin conditions using high krafft temperature anionic surfactantsARCUTIS BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4969US2025090535A1Stable formulations of shr0302ARCUTIS BIOTHERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 5069US2025144084A1Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drugARCUTIS BIOTHERAPEUTICS INC·Filed 2024·Application pending·0 cites
Showing the top 50 of 54 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →